Randox Laboratories and Roquefort Therapeutics Collaborate to Develop Midkine Cancer Antibodies
Randox and Roquefort Therapeutics collaborate to develop midkine cancer antibodies
Randox Laboratories collaborate with Roquefort Therapeutics, an LSE market listed biotech company, dedicated to developing first in class medicines in the high value, high growth oncology market. The partnership is focused on the field of medical diagnostics only, in relation to Roquefort’s Midkine antibody portfolio.
The collaboration Randox will allow to utilise Roquefort’s Midkine antibodies in the field of medical diagnostics. Randox will therefore engage with Roquefort in research programmes to identify new cancer diagnostics that will be treatable with the companies Midkine products.
Why this partnership is important?
Midkine is a herapin binding protein, known for being important in embryonic development. While normally undetected in healthy adults, it is often highly expressed in cancer, inflammatory conditions and autoimmune disorders. Extensive research has revealed that blocking Midkine with antibodies can help slow tumour growth, reduce metastasis and overcome treatment resistance.
Within the partnership, Randox focuses on medical diagnostics to detect cancers expressing Midkine, produce the diagnostics essential for clinical trials and help Roquefort Therapeutics remain focused on developing first in class oncology medicines.
Randox are highly committed to preventative healthcare through early and more accurate diagnostics therefore this partnership with Roquefort Therapeutics is vitally important. Early diagnosis significantly increases a patient’s chance of survival thus using medical diagnostics to identify patients with cancer expressing Midkine is essential to the development of first-in-class cancer medicines and the future of cancer treatments.
When talking about the partnership, Dr Peter Fitzgerald, Managing Director of Randox said
About Roquefort Therapeutics
Roquefort Therapeutics is a cancer focused biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort successfully acquired Lyramid Pty Ltd, a leader in the development of medicines for a new therapeutic target, Midkine and has since developed a leadership position in Midkine intellectual property.
Roquefort Therapeutics’ focused portfolio consists of four fully funded, novel patent protected, pre-clinical, anti-cancer medicines that include:
- Midkine antibodies with significant in vivo efficacy and toxicology studies
- Midkine RNA therapeutics with novel anti-cancer gene editing action
- MK cell therapy with direct NK-mediate anti-cancer action and
- SiRNA targeting novel STAT-6 target in solid tumour showing significant in VIVO efficacy.
For more information, please contact email@example.com